Drug Type CAR-T |
Synonyms Anti-BCMA CAR T-cell therapy (OriginCell Therapeutics), Ori-CAR 002, Ori-CAR-002 + [1] |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Preclinical | China | 26 May 2021 | |
| Multiple Myeloma | Preclinical | China | 18 May 2021 |





